Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippi applies for you, and finds you a job.
| CEO | Nick Leschly |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 74 |
| Date Founded | 2014 |
| Headquarters | Cambridge, Massachusetts |
| Number of Locations | 1 |
| Revenue | $8,000 |
| Net Income | -$66,147,000 |
| Tax Rate | -0.0% |
| Total Assets | $110,865,000 |
| Ticker | SYBX |
Synlogic received early financing of $29.4M on 2014-07-22.
| Series | Round size | Date |
|---|---|---|
| Series A | $29.4M | 07/2014 |
| Series A | $5M | 10/2014 |
| Series B | $40M | 02/2016 |
| Series C | $42M | 05/2017 |
| Post Ipo Equity | $50M | 01/2018 |
| Post Ipo Equity | $80M | 06/2019 |
| Post Ipo Equity | $30M | 04/2021 |
| Post Ipo Equity | $45M | 09/2021 |
| Investors | Security type |
|---|---|
| New Enterprise Associates (NEA) | Series A |
| Atlas Venture | Series A |
| New Enterprise Associates (NEA) | Series A |
| Atlas Venture | Series A |
| Bill & Melinda Gates Foundation | Series A |
| New Enterprise Associates (NEA) | Series B |
| Deerfield | Series B |
| OrbiMed Advisors | Series B |
| Atlas Venture | Series B |
| Ally Bridge Group | Series C |
| New Enterprise Associates (NEA) | Series C |
| Aju IB Investment | Series C |
| CLI Ventures | Series C |
| Deerfield | Series C |
| Perceptive Advisors | Series C |
| OrbiMed Advisors | Series C |
| Arctic Aurora LifeScience | Series C |
| Rock Springs Capital | Series C |
| Atlas Venture | Series C |
| Daphne Teo | Series C |
| Ginkgo Bioworks Inc | Post Ipo Equity |
Synlogic's top competitor, Rigel Pharmaceuticals, earned an annual revenue of $179.3M.
Synlogic's smallest competitor is Neon Therapeutics with revenue of $1.6M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Rigel Pharmaceuticals | $83,403 | $179.3M | 158 | 7 |
| XenoPort, Inc. | - | $41.2M | 200 | - |
| Omeros | $84,137 | $29.9M | 265 | 4 |
| Epizyme | $86,952 | $37.4M | 124 | - |
| Neon Therapeutics | $45,868 | $1.6M | 50 | - |
| Astellas Gene Therapies | $45,841 | $6.0M | 76 | - |
| OriGene | $63,076 | $7.8M | 105 | - |
| Aura Biosciences | $44,823 | $2.1M | 33 | 7 |
| Evelo Biosciences | $45,663 | $11.3M | 75 | - |
Zippia gives an in-depth look into the details of Synlogic, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Synlogic. The employee data is based on information from people who have self-reported their past or current employments at Synlogic. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Synlogic. The data presented on this page does not represent the view of Synlogic and its employees or that of Zippia.
Synlogic may also be known as or be related to SYNLOGIC INC., SYNLOGIC, INC., Synlogic, Synlogic Inc and Synlogic, Inc.